Table 3 aGVHD characteristics.

From: Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias

  

ATLG + PTCy 25

    

Diagnosis

Age

aGVHD onset, days

 

Stage

 

Grade

   

Skin

Lower GI

Liver

 

AML

52

90

3

0

0

2

AML

51

88

3

0

0

2

AML

54

26

2

3

0

3

ALL

22

76

2

3

0

3

ALL

34

31

3

0

0

2

ALL

25

42

3

0

0

2

ALL

28

35

2

2

2

3

ALL

25

20

3

0

0

2

  

PTCy 50

    

Diagnosis

Age

aGVHD onset, days

 

Stage

 

Grade

   

Skin

Lower GI

Liver

 

AML

54

39

2

0

0

1

AML

65

97

3

1

0

2

AML

34

22

3

1

1

2

AML

18

80

0

3

0

3

AML

41

124

3

0

0

2

AML

36

17

3

0

0

2

AML

28

20

3

0

0

2

AML

54

70

2

0

0

1

ALL

19

65

3

0

0

2

ALL

51

28

3

3

0

3

ALL

61

97

3

0

0

2

ALL

45

172

3

0

0

2

  1. ATLG Anti-T-lymphocyte globulin, PTCy Posttransplant cyclophosphamide, aGVHD Acute Graft-versus-host disease, AML Acute Myeloid Leukemia, ALL Acute Lymphoblastic Leukemia, GI Gastrointestinal.
Back to article page